Phase 2 cohort-2 trial in progress: Vabametkib plus lazertinib for patients with EGFR-mutant NSCLC who developed resistance to 1st-line, 3rd-gen-EGFR TKIs via C-Met dysregulation. A randomized phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results